Evaluation of a community intervention program in Japan using Framingham risk score and estimated 10-year coronary heart disease risk as outcome variables: a non-randomized controlled trial

  • Bing Zhu1, 3,

    Affiliated with

    • Yasuo Haruyama1Email author,

      Affiliated with

      • Takashi Muto1,

        Affiliated with

        • Akiko Yamasaki2 and

          Affiliated with

          • Fumiko Tarumi2

            Affiliated with

            BMC Public Health201313:219

            DOI: 10.1186/1471-2458-13-219

            Received: 21 July 2012

            Accepted: 6 March 2013

            Published: 11 March 2013

            Abstract

            Background

            Community-based programs are being widely adopted in the struggle to prevent cardiovascular diseases. No study has been conducted in Japan to evaluate the effects of a community-based health promotion program by using the Framingham risk score and 10-year CHD risk as outcome variables. The aim of the present study was to assess the effects of a program involving 6-month intervention and 18-month follow-up using such outcomes.

            Methods

            Participants (n = 1,983, 39.5% women, mean age 63.4 years) were selected for the study in 2008. Of these 1,983, 347 (42.4% women) subjects received the 6-month intervention. The intervention included individual counseling and group sessions, among others. After 18 months, 1,278 participants (intervention group: 238, control group: 1,040) were followed up. Changes in the Framingham risk score and 10-year coronary heart disease (CHD) risk were evaluated. ANCOVA and multiple logistic models adjusted for baseline value, age, sex and intervention times were used.

            Results

            The results showed that the differences in the Framingham risk score and mean 10-year CHD risk were significant in the intervention group compared with the control group after 6-month follow-up (-0.46 and -1.12, respectively) and were also significant after 18-month follow-up (-0.39 and -0.85, respectively). The proportion of those with intermediate 10-year CHD risk (> = 10%) was significantly lower at 6 months (OR 0.30, 95% CI 0.12-0.74) and at 18 months (OR 0.41, 95% CI 0.19-0.92).

            Conclusions

            The six-month intervention program effectively decreased estimated 10-year CHD risk and the effects were still present at 18-month follow-up.

            Trial registration

            UMIN-CTR: UMIN000008163

            Keywords

            Coronary disease Lifestyle Prevention Risk factors

            Background

            Morbidity and mortality due to cardiovascular disease are now the leading public health problems in industrialized countries, including Japan [1, 2]. Heart disease is the second leading cause of mortality in Japan [2].

            Community-based programs are being widely adopted in the struggle to prevent cardiovascular diseases. Community approaches to cardiovascular disease (CVD) prevention are attractive, since they can target all groups in the community and, if effective, may achieve widespread behavioral change and risk reduction. A number of community CVD prevention programs have been implemented over the last 40 years [3].

            As the incidence of cardiovascular disease is largely explained by modifiable risk factors (serum cholesterol and reduced high-density-lipoprotein cholesterol, blood pressure and cigarette smoking), reducing risk factors through health promotion focusing on lifestyle is a logical way of preventing disease [4].

            In the meantime, as evidence-based health promotion is becoming more and more important, outcome evaluation variables are needed by experts to evaluate the effect of health promotion programs. Since it is not appropriate to trace the incidence of cardiovascular disease for an intervention study, estimation equations to evaluate the incidence rate have been widely adopted. The Framingham risk score used to evaluate 10-year coronary heart disease (CHD) risk is the most popular estimation equation, which was derived from the Framingham Heart Study [58]. Many intervention studies implemented in Western countries have used the Framingham risk score to evaluate the effect of intervention studies [915].

            In Asia, although there has been some controversy over whether the Framingham risk score overestimates the risk of CHD in Asian populations [16, 17], it is still used by experts to provide useful information on future CHD events [18, 19].

            To our knowledge, this study is the first to use the Framingham risk score and 10-year CHD risk to evaluate the effects of a community-based health promotion program in Japan.

            The hypothesis in this study was that, similar to studies conducted in Western countries, lifestyle interventions could reduce the Framingham risk score and estimated 10-year CHD risk after 18-month follow-up relative to a control group.

            The aim of the present study was to assess the effect of a program involving six-month intervention and 18-month follow-up in a Japanese community using Framingham risk score and 10-year CHD risk as outcome variables.

            Methods

            Study design

            The Ministry of Health, Labour and Welfare (MHLW) in Japan started the “Specific Health Check-up Project” nationally in 2008. This study was one part of the project, which was implemented in Soka City in Saitama Prefecture, Japan, with a population of about 233,000 [20, 21].

            The present study employed a non-randomized controlled trial design. The program was provided from 2008 to 2010, including a 6-month intervention program and an 18-month follow-up program.

            Participants

            About 50,000 residents aged from 40–74 were invited to receive a health check-up. As shown in Figure 1, 12,961 residents aged 40–75 years old underwent health check-ups in 2008 and completed the baseline lifestyle questionnaire. Of these 12,961 subjects, 1,983 were selected for the study according to the following inclusion criteria [22], which were separated into two steps: (1) waist circumferences of the subjects as follows: ①waist circumference > =85 cm for males,> = 90 cm for females; ②waist circumference < 85 cm for males, <90 cm for females, and body mass index (BMI) > =25 kg/m2; (2) at least one of the following: hemoglobin (HbA1c) >5.2% (JDS, Japan Diabetes Society) (equal to >5.6% [NGSP, National Glycohemoglobin Standardization Program]) [23] or taking diabetes medication; triglycerides (TG) >150 mg/dl or high-density-lipoprotein cholesterol (HDL-C) <40 mg/dl or taking lipid-lowering medication; systolic blood pressure (SBP) > =130 mmHg or diastolic blood pressure (DBP) > =85 mmHg or taking hypertension medication; and having a history of smoking. The subjects who were taking diabetes, lipid-lowering and hypertension medication and were diagnosed as hypertension (SBP/DBP > = 140/90 mmHg), hyperlipidemia (LDL > =140 mg/dl or HDL <40 mg/dl or TG > = 150 mg/dl), diabetes (Fasting blood glucose > = 126 mg/dl or HbA1c > = 6.1% (JDS) (equal to > =6.5% [NGSP])) were advised to be seen by physicians, and were withdrawn from this study. The 1,983 subjects were informed about the program by direct mail and were then allocated into either the intervention or the control group according to the participants’ desire. The numbers of subjects in the intervention and control groups were 347(200 males and 147 females) and 1,636 (999 males and 637 females), respectively. After 6-month follow-up, 1,288 (251 in the intervention group and 1,037 in the control group) participants underwent the second health check-up and completed the lifestyle questionnaire. Finally, after the 18-month follow-up, 1,278 participants (238 in the intervention group and 1,040 in the control group) completed the final health check-up and lifestyle questionnaire in 2010 (Figure 1).
            http://static-content.springer.com/image/art%3A10.1186%2F1471-2458-13-219/MediaObjects/12889_2012_5118_Fig1_HTML.jpg
            Figure 1

            Flowchart of the study protocol.

            Risk factor measurements

            All of the measurements were provided by medical institutions. Body weight and height were measured with no shoes and excess clothing removed on the same calibrated scale at the baseline, 6-month and 18-month follow-up. BMI was calculated as body weight (kg) divided by the square of the height (m2). Waist circumference was measured by nurses. SBP and DBP were measured using auto-manometers (Omron Co., Tokyo, Japan). Fasting blood samples from all subjects were obtained and TG, low-density lipoprotein cholesterol (LDL-C), HDL-C and HbA1c were measured at a laboratory (Saitama, Japan).

            Subjects with overweight were defined as having a BMI > =25 kg/m2; subjects with hypertension risk were defined as having at least one of the following: SBP > =130 mmHg or DBP > =85 mmHg; subjects with dyslipidemia risk were defined as having at least one of the following: HDL-C <40 mg/dl, LDL-C > =140 mg/dl or TG > =150 mg/dl; subjects with diabetes risk were defined as having a HbA1c > 5.2% (JDS) (equal to >5.6% [NGSP]).

            We used the Framingham risk score, which is based on age, TC, HDL-C, SBP and current smoking status, in order to establish risk scores [8]. HDL-C was classified into 4 levels (> = 60, 50–59, 40–49, <40 mg/dl). SBP was classified into 5 levels (<120,120-129,130-139,140-159,> = 160 mmHg). TC was calculated according to the Friedewald equation [24]. Estimated 10-year CHD risk was evaluated according to the Framingham risk score [8]. Moreover, we also used intermediate 10-year CHD risk with a definition of > =10% [8].

            Assessment of lifestyle variables

            Information on lifestyle factors such as smoking, drinking alcohol, dietary behaviors and physical activity, medical history and sleeping was obtained by a self-administered questionnaire at the baseline, 6 and 18 months.

            Current smokers were defined as those who had been smoking for 6 months or had smoked over 100 cigarettes and were still smoking in the previous month. Drinking alcohol was indicated by the frequency of drinking and the amount of alcohol consumption per day. Dietary behaviors included eating speed, usual time for eating supper, eating snacks and skipping breakfast. Physical activity included regular exercise, daily physical activity and walking speed. Sleeping status was categorized as well or not well.

            In this study, the preferable lifestyle behaviors were defined as follows: no smoking, exercise over 30 minutes and 2 times per week, walking or having physical activity over 1 hour every day, walking faster than their peers, not eating fast, not eating dinner less than 2 hours before sleeping, not eating snacks over 3 times every week, not skipping breakfast over 3 times every week, not drinking alcohol every day, drinking alcohol less than 22 g and sleeping well.

            Intervention

            All subjects in the intervention and control groups were given 3 health checkups and 3 lifestyle surveys at the baseline, 6-month follow-up, and 18-month follow-up.

            The common program consisted of a lecture regarding the purpose of health promotion at the baseline and newsletters featuring general health information provided by local community health workers during the 18-month period.

            For the intervention group, a comprehensive program consisting of a 6-month intervention was provided. The 6-month intervention program included individual counseling and group sessions, in addition to the common program.

            Individual counseling

            Individual counseling was conducted on the basis of the results of health check-ups and health assessment charts on lifestyle at the baseline (60 minutes per person).

            Group sessions

            The group sessions focused on nutrition and exercise (a total of 12 times of 60–120 minutes duration). The nutrition group sessions included talks, a lecture, cooking demonstrations and motivational interviewing. The exercise group sessions included aerobic exercises, stretching, walking and other exercises in a gym or local health or community center. The same program was provided during the daytime and at night for the convenience of participants. Through these approaches, participants were encouraged to set their own goals for lifestyle modification.

            Other interventions by telephone and letter

            The other interventions included contact by telephone (a total of 3 times of 5–15 minutes duration) and letter (a total of 3 times). Through telephone calls and letters, subjects were advised to attend the group sessions and motivated to change their lifestyle behaviors. Those who were absent from the group sessions were also followed up by telephone or letter to inquire about the reason. The changes in lifestyle behaviors among the subjects were also evaluated by questions over the telephone.

            Statistical analysis

            We selected lifestyle behaviors and cardiovascular disease risks as outcome measures in this study. Lifestyle behaviors included smoking, dietary behaviors, physical activity, drinking alcohol and sleeping. Cardiovascular disease risks included weight, BMI, waist circumference, SBP, DBP, HDL-C, LDL-C, TG and HbA1c.

            Baseline cardiovascular disease risk and lifestyle behavior differences were analyzed by Student’s t-test for continuous variables, Mann–Whitney test for nonparametric variables and Chi-squared test for categorical variables.

            The mean differences in changes in cardiovascular disease risk factors at 6 and 18 months between the intervention and control groups were assessed by covariance analysis adjusted for the baseline value, age, sex and intervention times. Comparisons of lifestyle behaviors at 6 and 18 months between the intervention and control groups were conducted by multiple logistic regression analysis adjusted for the baseline category, age and sex. The odds ratios (OR) and 95% confidence interval (95% CI) were used to indicate the relative risk ratio between the intervention and control groups. In addition, we determined the probability of risk in subjects with overweight, hypertension risk, dyslipidemia risk, diabetes risk, metabolic syndrome and 10-year CHD risk by multiple logistic regression analysis adjusted for the baseline category, age, sex and intervention times. All statistical analyses were performed using an assumed type I error rate of 0.05. Statistical analyses were performed using SPSS Statistics 20.0 for Windows (SPSS Japan Inc., Tokyo, Japan).

            Ethical consideration

            Ethical approval was given by the ethics committee at Dokkyo Medical University (No2057).

            Results

            Baseline characteristics of participants

            The baseline characteristics of the study participants are presented in Table 1. The mean age in the intervention group was significantly higher than that in the control group (P < 0.001). In addition, the baseline characteristics of the completed and drop-out subjects in the intervention group were compared (not shown in Table). In 2009, the mean age in the drop-out group was younger than that in the completed group (P = 0.006). In 2010, weight and mean 10-year CHD risk were higher and HDL-C was lower in the drop-out group than in the completed group (P = 0.012, 0.018 and 0.011 respectively). Other variables including the Framingham risk score showed no significant differences between the two groups.
            Table 1

            Characteristics of baseline cardiovascular disease risks and lifestyle behaviors between intervention and control groups

             

            Intervention N = 347

            Control N = 1,636

            P-valuea

             

            Mean ± S.D.

            Mean ± S.D.

             

            Age, year

            65.0 ± 7.8

            63.0 ± 8.8

            <0.001

            Weight, kg

            66.1 ± 8.1

            66.8 ± 9.2

            0.166

            BMI, kg/m2

            25.8 ± 2.3

            25.8 ± 2.4

            0.960

            Waist, cm

            91.0 ± 5.8

            90.9 ± 6.2

            0.942

            SBP, mmHg

            134.0 ± 14.6

            135.5 ± 16.6

            0.121

            DBP, mmHg

            79.7 ± 9.7

            80.8 ± 10.5

            0.077

            HDL-C, mg/dl

            57.3 ± 14.5

            56.2 ± 14.9

            0.179

            LDL-C, mg/dl

            134.0 ± 29.6

            133.8 ± 32.1

            0.933

            TG, mg/dl

            151.1 ± 95.8

            165.8 ± 130.7

            0.287b

            HbA1c,%

            5.34 ± 0.47

            5.38 ± 0.82

            0.395

            Framingham risk score, score

            14.0 ± 2.5

            13.7 ± 2.9

            0.085

            Mean 10-year CHD risk,%

            9.3 ± 6.0

            9.4 ± 6.4

            0.646

             

            N (%)

            N (%)

             

            Sex

               

            male

            200 (57.6)

            999 (61.1)

            0.236

            female

            147 (42.4)

            637 (38.9)

            Current smoker

            62 (17.9)

            384 (23.5)

            0.023

            Physical activity

               

            Exercise over than 30 min, > = 2 times/week

            159 (51.6)

            595 (39.7)

            <0.001

            Walking or physical activity over than 1 hour every day

            168 (54.9)

            707 (47.3)

            0.015

            Walking faster than their peers

            171 (55.9)

            771 (52.1)

            0.231

            Dietary behavior

               

            Eating fast

            88 (28.5)

            410 (27.4)

            0.686

            Eating dinner less than 2 hours before sleeping

            62 (20.1)

            406 (27.2)

            0.009

            Eating snacks over than 3 times every week

            42 (13.6)

            200 (13.4)

            0.900

            Skipping breakfast over than 3 times every week

            22 (7.1)

            218 (14.6)

            <0.001

            Drinking alcohol every day

            156 (50.5)

            669 (44.7)

            0.063

            Drinking alcohol less than 22 g

            143 (60.9)

            666 (56.8)

            0.249

            Sleeping well

            247 (81.0)

            1148 (77.2)

            0.147

            BMI = body mass index, waist = waist circumference, SBP = systolic blood pressure, DBP = diastolic blood pressure, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, TG = Triglycerides, HbA1c = Hemoglobin, CHD = coronary heart disease.

            aby chi-squared or Student’s t-test.

            bby Mann–Whitney test.

            The proportions of those with current smoking (P = 0.023), eating dinner late (P = 0.009) and skipping breakfast (P < 0.001) were significantly lower in the intervention group than those in the control group. The proportions of those with regular exercise (P < 0.001) and daily physical activity (P = 0.015) were significantly higher in the intervention group than those in the control group. There were no other significant differences in baseline characteristics between the two groups.

            The number of interventions in the intervention group was an average of 7.1 (range from1 to15) (not show in Table).

            Changes in lifestyle behaviors

            Table 2 shows the odds ratios of preferable lifestyle behaviors in the intervention group versus the control group. Multiple logistic regression analysis adjusted for each baseline category, age and sex showed that the proportion of those performing regular exercise was significantly higher in the intervention group than in the control group at 6 months (OR 1.79, 95% CI 1.24-2.59). The proportion of those who walked or did physical activity over 1 hour every day was significantly higher in the intervention group than in the control group at 6 months (OR 1.51, 95% CI 1.06-2.14). The proportion of those who walked faster than their peers was significantly higher in the intervention group than in the control group at 6 months (OR 1.45, 95% CI 1.01-2.09). The proportion of those who ate snacks over than 3 times every week was significantly lower in the intervention group than in the control group at 6 months (OR 0.35, 95% CI 0.17-0.71) and it was still lower at 18 months (OR 0.48, 95% CI 0.23-0.98). There were no other significant differences in lifestyle behaviors between the two groups. Moreover, in 2009, 37 people (6 in the intervention group and 31 in the control group) stopped smoking after 6-month follow-up, which accounted for 2.9%; in 2010, 58 people (9 in the intervention group and 49 in the control group) stopped smoking after 18-month follow-up, which accounted for 4.5%.
            Table 2

            Comparison of changes in lifestyle behavior between intervention and control groups

             

            At 6 months 251 vs. 1,037

            At 18 months 238 vs. 1,040

             

            ORa

            95%CI

            ORa

            95%CI

            Current smoker

            0.83

            0.37-1.87

            0.62

            0.30-1.28

            Physical activity

                

            Exercise over 30 min, > = 2 times/week

            1.79

            1.24-2.59

            1.27

            0.90-1.80

            Walking or physical activity over than 1 hour every day

            1.51

            1.06-2.14

            1.30

            0.93-1.82

            Walking faster than their peers

            1.45

            1.01-2.09

            1.06

            0.74-1.52

            Dietary behavior

                

            Eating fast

            1.45

            0.91-2.30

            0.98

            0.61-1.57

            Eating dinner less than 2 hours before sleeping

            0.82

            0.52-1.29

            0.68

            0.43-1.09

            Eating snacks over than 3 times every week

            0.35

            0.17-0.71

            0.48

            0.23-0.98

            Skipping breakfast over than 3 times every week

            0.45

            0.18-1.09

            0.42

            0.16-1.15

            Drinking alcohol every day

            0.78

            0.42-1.45

            1.23

            0.78-1.94

            Drinking alcohol less than 22 g

            1.57

            0.92-2.68

            1.28

            0.77-2.15

            Sleeping well

            1.01

            0.65-1.56

            0.88

            0.57-1.35

            aby multiple logistic regression analysis adjusted for baseline category, age and sex.

            Changes in cardiovascular disease risks

            Baseline to 6-month changes in cardiovascular disease risks between the two groups are displayed in Table 3. Presented below and in the tables are the unadjusted means and adjusted P values by using covariance analysis controlling for age, sex, baseline values and intervention times.
            Table 3

            Comparison of changes in cardiovascular disease risk between intervention and control groups at 6-month follow-up

             

            N

            Baseline

            6-month

            Intervention vs. Control

               

            Mean ± S.D.

            Mean ± S.D.

            Difference

            P-valuea

            Weight, kg

            Intervention

            251

            65.6 ± 8.0

            63.7 ± 8.2

            -0.93

            0.002

            Control

            1037

            65.7 ± 8.3

            65.2 ± 8.6

            BMI, kg/m2

            Intervention

            251

            25.8 ± 2.2

            25.1 ± 2.3

            -0.37

            0.004

            Control

            1037

            25.6 ± 2.2

            25.4 ± 2.4

            Waist, cm

            Intervention

            250

            90.9 ± 5.9

            88.5 ± 6.6

            -0.77

            0.129

            Control

            1036

            90.3 ± 5.6

            89.6 ± 6.3

            SBP, mmHg

            Intervention

            251

            133.7 ± 14.0

            130.8 ± 13.0

            -1.77

            0.212

            Control

            1037

            134.8 ± 15.5

            133.0 ± 15.0

            DBP, mmHg

            Intervention

            251

            80.0 ± 9.4

            77.4 ± 8.7

            -1.54

            0.092

            Control

            1036

            80.4 ± 10.3

            79.3 ± 9.7

            HDL-C, mg/dl

            Intervention

            251

            57.9 ± 15.2

            58.5 ± 15.1

            0.91

            0.267

            Control

            1037

            56.8 ± 15.1

            56.6 ± 15.3

            LDL-C, mg/dl

            Intervention

            250

            134.7 ± 30.1

            130. ± 30.3

            2.78

            0.227

            Control

            1036

            131.9 ± 30.9

            129.4 ± 29.7

            TG, mg/dl

            Intervention

            251

            141.1 ± 65.8

            130.8 ± 71.0

            -14.9

            0.150

            Control

            1036

            158.8 ± 125.9

            148.2 ± 114.3

            HbA1c,%

            Intervention

            251

            5.33 ± 0.43

            5.25 ± 0.38

            -0.05

            0.179

            Control

            1033

            5.33 ± 0.62

            5.33 ± 0.57

            Framingham risk score, score

            Intervention

            250

            14.0 ± 2.4

            13.9 ± 2.4

            -0.46

            0.002

            Control

            1029

            13.9 ± 2.7

            13.9 ± 2.9

            Mean 10-year CHD risk, %

            Intervention

            250

            9.1 ± 5.9

            8.9 ± 6.0

            -1.12

            0.001

             

            Control

            1030

            9.4 ± 6.2

            9.6 ± 6.5

              

            BMI = body mass index, waist = waist circumference, SBP = systolic blood pressure, DBP = diastolic blood pressure, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, TG = Triglycerides, HbA1c = Hemoglobin, CHD = coronary heart disease.

            aby covariance analysis adjusted for baseline values, age, sex and intervention times.

            The mean decreases in weight (P = 0.002) and BMI (P = 0.004) in the intervention group showed significant differences compared with those in the control group. The average Framingham risk score in the intervention group showed a significant decrease (P = 0.002). The mean 10-year CHD risk also showed a significant decrease in the intervention group (P = 0.001).

            HDL-C and LDL-C in the intervention group showed slight increases compared with those in the control group, but the increases were not statistically significant. All other cardiovascular disease risks showed a decrease in the intervention group, but the reductions were not statistically significant.

            The changes in cardiovascular disease risks between the two groups at 18 months are shown in Table 4. Covariance analysis adjusted for baseline values, age, sex and intervention times showed that the average weight (P = 0.003), BMI (P = 0.007), waist circumference (P = 0.039) and TG (P = 0.021) in the intervention group were significantly decreased at 18 months. The Framingham risk score (P = 0.022) and mean 10-year CHD risk (P = 0.027) were significantly decreased in the intervention group compared with those in the control group. DBP, HDL-C and LDL-C in the intervention group showed slight increases compared with those in the control group, but the increases were not statistically significant. All other cardiovascular disease risks showed a decrease in the intervention group, but the reductions were not statistically significant.
            Table 4

            Comparison of changes in cardiovascular disease risk between intervention and control groups at 18-month follow-up

             

            N

            Baseline

            18-month

            Intervention vs. Control

              

            Mean ± S.D.

            Mean ± S.D.

            Difference

            P-valuea

            Weight, kg

            Intervention

            238

            65.4 ± 7.9

            63.8 ± 8.2

            -1.08

            0.003

            Control

            1040

            66.0 ± 8.7

            65.4 ± 9.2

            BMI, kg/m2

            Intervention

            238

            25.7 ± 2.2

            25.1 ± 2.3

            -0.38

            0.007

            Control

            1040

            25.7 ± 2.3

            25.5 ± 2.6

            Waist, cm

            Intervention

            238

            90.8 ± 5.7

            88.9 ± 6.5

            -1.13

            0.039

            Control

            1040

            90.6 ± 5.9

            90.0 ± 6.7

            SBP, mmHg

            Intervention

            238

            133.9 ± 14.5

            131.2 ± 14.0

            -0.91

            0.520

            Control

            1040

            135.2 ± 16.1

            132.4 ± 14.8

            DBP, mmHg

            Intervention

            238

            79.6 ± 9.6

            78.1 ± 9.0

            0.27

            0.778

            Control

            1040

            80.7 ± 10.5

            78.4 ± 9.9

            HDL-C, mg/dl

            Intervention

            238

            58.6 ± 15.0

            58.6 ± 14.8

            1.10

            0.214

            Control

            1040

            56.6 ± 15.1

            56.3 ± 15.3

            LDL-C, mg/dl

            Intervention

            238

            134.2 ± 29.1

            127.0 ± 27.9

            0.59

            0.823

            Control

            1040

            133.9 ± 31.5

            127.5 ± 31.7

            TG, mg/dl

            Intervention

            238

            143.6 ± 74.2

            136.5 ± 76.2

            -25.1

            0.021

            Control

            1040

            163.4 ± 131.1

            156.7 ± 119.4

            HbA1c,%

            Intervention

            238

            5.32 ± 0.39

            5.31 ± 0.39

            -0.03

            0.429

            Control

            1040

            5.35 ± 0.66

            5.38 ± 0.57

            Framingham risk score, score

            Intervention

            238

            13.9 ± 2.4

            14.0 ± 2.5

            -0.39

            0.022

            Control

            1040

            13.9 ± 2.7

            14.1 ± 2.9

            Mean 10-year CHD risk,%

            Intervention

            238

            8.7 ± 5.8

            8.8 ± 5.9

            -0.85

            0.027

             

            Control

            1040

            9.3 ± 6.4

            9.8 ± 6.6

              

            BMI = body mass index, waist = waist circumference, SBP = systolic blood pressure, DBP = diastolic blood pressure, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, TG = Triglycerides, HbA1c = Hemoglobin, CHD = coronary heart disease.

            aby covariance analysis adjusted for baseline values, age, sex and intervention times.

            Table 5 shows the odds ratios of cardiovascular disease risks in the intervention group versus the control group. Multiple logistic regression analysis adjusted for each baseline category, age, sex and intervention times showed that the proportion of those with intermediate 10-year CHD risk (> = 10%) was significantly lower in the intervention group than in the control group at 6 months (OR 0.30, 95% CI 0.12-0.74) and at 18 months (OR 0.41, 95% CI 0.19-0.92). The proportion of those with dyslipidemia risk was significantly lower in the intervention group than in the control group at 18 months (OR 0.59, 95% CI 0.36-0.97).
            Table 5

            Odds ratios of cardiovascular risks in intervention versus control group at each risk with baseline

             

            At 6 months 251 vs. 1,037

            At 18 months 238 vs. 1,040

             

            ORa

            95%CI

            ORa

            95%CI

            Overweight

            0.62

            0.34-1.10

            0.56

            0.31-1.01

            Hypertension risk

            1.06

            0.66-1.70

            0.79

            0.49-1.27

            Dyslipidemia risk

            0.75

            0.45-1.24

            0.59

            0.36-0.97

            Diabetes risk

            0.71

            0.35-1.46

            0.65

            0.32-1.29

            Intermediate 10-year CHD risk (> = 10%)

            0.30

            0.12-0.74

            0.41

            0.19-0.92

            CHD = coronary heart disease.

            aby multiple logistic regression analysis adjusted for baseline category, age, sex and intervention times.

            Discussion

            The major finding of the present study is a significant decrease in the mean 10-year CHD risk at 6-month follow-up and that the effects were still sustained at 18-month follow-up. The number of subjects with intermediate 10-year CHD risk (> = 10%) also decreased significantly at each follow-up time.

            A previous study also showed significant change in 10-year CHD risk after lifestyle intervention. The results from the PREMIER Trial showed that, in individuals with prehypertension or stage 1 hypertension, 2 multicomponent behavioral interventions (EST + DASH and EST) significantly reduced the estimated 10-year CHD risk by 12% and 14%, respectively [9]. The DEPLOY pilot study indicated that community-based delivery of the DPP lifestyle intervention could have a significant effect on prevention of CHD in overweight adults with abnormal glucose metabolism. At 4 and 12 months, the intervention group experienced significant decreases in 10-year risk from baseline (-3.28%, P < 0.001; and -2.23%, P = 0.037) compared with control subjects (-0.78%, P = 0.339; and +1.88%, P = 0.073) [14]. The California WISEWOMAN Project reported that the improvement in the 10-year CHD risk was greater for an enhanced intervention group (EIG) than for a usual care group (UCG), and this improvement was significantly greater when the women’s CHD risk levels were in the upper quartile at baseline [15].

            From the results of our study, other cardiovascular disease risk factors did not show significant results, except for weight and BMI. This may have been caused by the 10-year CHD risk reflecting the comprehensive effect of intervention. Maybe some of the cardiovascular disease risk factors changed a little, but this was still not significant. When we combined the changes in cardiovascular disease risk factors together into the 10-year CHD risk, it showed a significant change.

            The present study also showed the sustainment of the effect when the intervention was stopped after 18-month follow-up. This proved that the effect of a short-term intervention can be sustained after a long-term follow-up period, greater than one year.

            Similar results were also shown in other previous studies. Lindstrom et al. found that lifestyle intervention in people at high risk for type 2 diabetes resulted in sustained lifestyle changes, a modest difference in body weight change and reduction in diabetes incidence, which remained after the individual lifestyle counseling stopped [25]. A study conducted by Elmer et al. showed that, over 18 months, persons with prehypertension and stage 1 hypertension could sustain multiple lifestyle modifications that improve control of blood pressure and could reduce the risk for chronic disease [26]. Four-year results of the Look AHEAD Trial indicated that intensive lifestyle intervention can produce sustained weight loss and improvements in other CVD risk factors in individuals with type 2 diabetes [27].

            The results of the present study indicated significant decrease in weight and body mass index at 6-month follow-up. In addition, the reductions were sustained and showed significantly stronger decrease at 18-month follow-up. This proved that, by implementing lifestyle intervention, weight loss can be achieved, which is similar to the results of previous studies.

            In a lifestyle intervention study implemented among persons at high risk for cardiovascular disease and diabetes in a rural community, 52% of participants met the 7% weight loss goal and 66% achieved at least a 5% weight loss [28]. However, the sample size was very small (N = 84 and N = 65, respectively). A study conducted by Lindstrom et al. in 2003 indicated that, after 1 and 3 years, weight reductions were 4.5 and 3.5 kg in the intervention group and 1.0 and 0.9 kg in the control group, respectively [29]. In the present study, weight reduction was 1.5 kg in the intervention group and 0.6 kg in the control group after 18 months.

            The present study has limitations. Firstly, our study has a non-randomized study design. The participants were allocated to either the intervention or the control group on the basis of each participant’s desire. The subjects with a strong desire to improve their lifestyle were more inclined to accept the intervention and then acquired a better effect of changes in cardiovascular disease risk and lifestyle behavior. However, since the baseline cardiovascular disease risk factors were similar in the two groups, the non-randomized study design may not affect the main significant results in the changes of cardiovascular disease risk in our study.

            Secondly, the assessment of lifestyle behavior change in the study was based on a self-reported questionnaire. This may have resulted in some recall bias when evaluating the change in lifestyle behavior and have led to little significant change in lifestyle behavior between the intervention and control groups. Further study should focus on a detailed method to evaluate the change in lifestyle behavior, such as using pedometers to measure change in physical activity.

            Thirdly, this study has a high drop-out rate. On the one hand, as the results showed, younger people were more inclined to withdraw from our study, maybe because they were not interested in the form of the intervention. For example, younger people may prefer to choose more vigorous exercises instead of the jogging and gymnastics done in our study. On the other hand, subjects with higher BMI, thus having higher 10-year CHD risk, were more inclined to withdraw from our study, which limited the significance of the results.

            Lastly, the number of participants was relatively small, especially in the intervention group, which might have limited the significance of the results and the generalization to the middle-aged Japanese population. Regarding the generalization of this study, the intensity of intervention that targeted a large percentage of the population who are at high risk of CVD may have been too strong. In a future study, a new method of intervention of less intensity should be developed, which can be applied worldwide, considering the limited ability of health services in many areas.

            Conclusions

            Our study demonstrates that the six-month intervention program effectively improved the cardiovascular disease risk and estimated 10-year CHD risk. Moreover, the effects were still present at the 18-month follow-up.

            Consent

            Written informed consent was obtained from the patient for publication of this report and any accompanying images.

            Declarations

            Acknowledgments

            The authors wish to thank the staff of Soka City Health Center and Soka City Office who worked on or cooperated with the present project, as well as the citizens of Soka City. This study was supported by grants from Soka City and supported in part by Japan China Sasakawa Medical Fellowship.

            Authors’ Affiliations

            (1)
            Department of Public Health, Dokkyo Medical University School of Medicine
            (2)
            Soka City Health Center
            (3)
            Division of Health Education, Anhui Provincial Center for Disease Control and Prevention

            References

            1. WHO: World health statistics 2009. Geneva: World Health Organization; 2009.
            2. Health, Labour and Welfare Statistics Association: Journal of health and welfare statistics. Tokyo: KousaidouInc; 2011. in Japanese
            3. Pennant M, Davenport C, Bayliss S, Greenheld W, Marshall T, Hyde C: Community Programs for the Prevention of Cardiovascular Disease: A Systematic Review. Am J Epidemiol 2010, 172:501–516.PubMedView Article
            4. Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Davey Smith G: Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev 2011, CD001561. http://​onlinelibrary.​wiley.​com/​doi/​10.​1002/​14651858.​CD001561.​pub3/​pdf
            5. Anderson KM, Odell PM, Wilson PW, Kannel WB: Cardiovascular disease risk profiles. Am Heart J 1991, 121:293–298.PubMedView Article
            6. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837–1847.PubMedView Article
            7. D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB: General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008, 117:743–753.PubMedView Article
            8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285:2486–2497.View Article
            9. Maruthur NM, Wang N-Y, Appel LJ: Lifestyle interventions reduce coronary heart disease risk: results from the PREMIER trial. Circulation 2009, 119:2026–2031.PubMedView Article
            10. Wister A, Loewen N, Kennedy-Symonds H, McGowan B, McCoy B, Singer J: One-year follow-up of a therapeutic lifestyle intervention targeting cardiovascular disease risk. CMAJ 2007, 177:859–865.PubMedView Article
            11. Price D, Ramachandran S, Knight T, Jones PW, Neary RH: Observed changes in the lipid profile and calculated coronary risk in patients given dietary advice in primary care. Br J Gen Pract 2000, 50:712–715.PubMed
            12. Ellsworth DL, O’Dowd SC, Salami B, Hochberg A, Vernalis MN, Marshall D, Morris JA, Somiari RI: Intensive lifestyle modification: impact on cardiovascular disease risk factors in subjects with and without clinical cardiovascular disease. Prev Cardiol 2004, 7:168–175.PubMedView Article
            13. Richardson G, van Woerden HC, Morgan L, Edwards R, Harries M, Hancock E, Sroczynsk S, Bowley M: Healthy Hearts-A community-based primary prevention programme to reduce coronary heart disease. BMC Cardiovasc Disord 2008, 8:18.PubMedView Article
            14. Lipscomb ER, Finch EA, Brizendine E, Saha CK, Hays LM, Ackermann RT: Reduced 10-year risk of coronary heart disease in patients who participated in a community-based diabetes prevention program: the DEPLOY pilot study. Diabetes Care 2009, 32:394–396.PubMedView Article
            15. Hayashi T, Farrell MA, Chaput LA, Rocha DA, Hernandez M: Lifestyle intervention, behavioral changes, and improvement in cardiovascular risk profiles in the California WISEWOMAN Project. J Womens Health (Larchmt) 2010, 19:1129–1138.View Article
            16. D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P, CHD Risk Prediction Group: Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001, 286:180–187.PubMedView Article
            17. Liu J, Hong Y, D’Agostino RB Sr, Wu Z, Wang W, Sun J, Wilson PW, Kannel WB, Zhao D: Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese multi-provincial cohort study. JAMA 2004, 291:2591–2599.PubMedView Article
            18. Suka M, Sugimori H, Yoshida K: Application of the updated Framingham risk score to Japanese Men. Hypertens Res 2001, 24:685–689.PubMedView Article
            19. Suka M, Sugimori H, Yoshida K: Validity of the Framingham risk model applied to Japanese Men. Methods Inf Med 2001, 41:213–215.
            20. Haruyama Y, Muto T, Nakade M, Kobayashi E, Ishisaki K, Yamasaki A: Fifteen-month lifestyle intervention program to improve cardiovascular risk factors in a community population in Japan. Tohoku J Exp Med 2009, 217:259–269.PubMedView Article
            21. Fujii H, Muto T, Haruyama Y, Nakade M, Kobayashi E, Ishisaki K, Yamasaki A: Community-based lifestyle modification of cardiovascular disease risks in middle-aged Japanese: a 27-month update. Tohoku J Exp Med 2010, 220:307–318.PubMedView Article
            22. Okamoto E, Kaneita Y, Kobashi G, Sakada K, Sato T, Yoshiike N: Subnote Medical care and Public Health 2012. Tokyo: MEDELIKKUMEDELIA Cop; 2011. (in Japanese)
            23. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, Hanafusa T, Haneda M, Ueki K: Report of the committee on the classification and diagnostic criteria of diabetes mellitus (revision for international harmonization of HbA1c in Japan). J Japan DiabSoc 2012, 55:485–514. in Japanese
            24. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499–502.PubMed
            25. Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, Hämäläinen H, Härkönen P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J, Finnish Diabetes Prevention Study Group: Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006, 368:1673–1679.PubMedView Article
            26. Elmer PJ, Obarzanek E, Vollmer WM, Simons-Morton D, Stevens VJ, Young DR, Lin PH, Champagne C, Harsha DW, Svetkey LP, Ard J, Brantley PJ, Proschan MA, Erlinger TP, Appel LJ, PREMIER Collaborative Research Group: Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med 2006, 144:485–495.PubMed
            27. Wing RR, Look AHEAD Research Group: Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus. Arch Intern Med 2010, 170:1566–1575.PubMedView Article
            28. Vadheim LM, Brewer KA, Kassner DR, Vanderwood KK, Hall TO, Butcher MK, Helgerson SD, Harwell TS: Effectiveness of a lifestyle intervention program among persons at high risk for cardiovascular disease and diabetes in a rural community. J Rural Health 2010, 26:266–272.PubMedView Article
            29. Lindström J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, Uusitupa M, Tuomileht J, Finnish Diabetes Prevention Study Group: The Finnish diabetes prevention study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003, 26:3230–3236.PubMedView Article
            30. Pre-publication history

              1. The pre-publication history for this paper can be accessed here:http://​www.​biomedcentral.​com/​1471-2458/​13/​219/​prepub

            Copyright

            © Zhu et al.; licensee BioMed Central Ltd. 2013

            This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.